Clinical pharmacokinetics of drugs used to treat urge incontinence

Guay, David R.P.
November 2003
Clinical Pharmacokinetics;Nov2003, Vol. 42 Issue 14, p1243
Academic Journal
journal article
Urge incontinence (also known as overactive bladder) is a common form of urinary incontinence, occurring alone or as a component of mixed urinary incontinence, frequently together with stress incontinence. Because of the pathophysiology of urge incontinence, anticholinergic/antispasmodic agents form the cornerstone of therapy. Unfortunately, the pharmacological activity of these agents is not limited to the urinary tract, leading to systemic adverse effects that often promote nonadherence. Although the pharmacokinetics of flavoxate, propantheline, scopolamine, imipramine/desipramine, trospium chloride and propiverine are also reviewed here, only for oxybutynin and tolterodine are there adequate efficacy/tolerability data to support their use in urge incontinence. Oxybutynin is poorly absorbed orally (2-11% for the immediate-release tablet formulation). Controlled-release oral formulations significantly prolong the time to peak plasma concentration and reduce the degree of fluctuation around the average concentration. Significant absorption occurs after intravesical (bladder) and transdermal administration, although concentrations of the active N-desethyl metabolite are lower after transdermal compared with oral administration, possibly improving tolerability. Food has been found to significantly affect the absorption of one of the controlled-release formulations of oxybutynin, enhancing the rate of drug release. Oxybutynin is extensively metabolised, principally via N-demethylation mediated by the cytochrome P450 (CYP) 3A isozyme. The pharmacokinetics of tolterodine are dependent in large part on the pharmacogenomics of the CYP2D6 and 3A4 isozymes. In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively. Tolterodine is metabolised via CYP2D6 to the active metabolite 5-hydroxymethyl-tolterodine and via CYP3A to N-dealkylated metabolites. Urinary excretion of parent compound plays a minor role in drug disposition. Drug effect is based upon the unbound concentration of the so-called 'active moiety' (sum of tolterodine + 5-hydroxymethyl-tolterodine). Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively. Coadministration of antacid essentially converts the extended-release formulation into an immediate-release formulation. Knowledge of the pharmacokinetics of these agents may improve the treatment of urge incontinence by allowing the identification of individuals at high risk for toxicity with 'usual' dosages. In addition, the use of alternative formulations (controlled-release oral, transdermal) may also facilitate adherence, not only by reducing the frequency of drug administration but also by enhancing tolerability by altering the proportions of parent compound and active metabolite in the blood.


Related Articles

  • Urispas 200.  // Royal Society of Medicine: Medicines;2002, p555 

    The article provides information on urispas 200, a proprietary, prescription-only preparation of the anticholinergic drug flavoxate hydrochloride. The drug can be used as an antispasmodic in the treatment of urinary frequency and incontinence. It is available as tablets.

  • scopolamine hydrobromide.  // Royal Society of Medicine: Medicines;2002, p489 

    This article presents information on scopolamine hydrobromide which is another name for hyoscine hydrobromide.

  • Most cost-effective therapies for urinary incontinence in Sweden….  // PharmacoEconomics & Outcomes News;1/7/2012, Issue 644, p7 

    The article discusses study on the cost effectiveness of newer anticholinergic drugs versus immediate-release oxybutynin in patients with urinary incontinence. It references a study by F. O. Nilsson et al in the November 17, 2011 issue of the "British Journal of Urology International." Data used...

  • dicyclomine.  // Davis's Drug Guide for Nurses, 10th edition;2007, p382 

    The article presents a nursing guide to dicyclomine, an antispasmodic and anticholinergic agent used for the management of irritable bowel syndrome in patients who do not respond to usual interventions. Indications and contraindications are mentioned. Adverse reactions to the drug are cited....

  • Citalopram/scopolamine.  // Reactions Weekly;2/4/2012, Issue 1387, p13 

    The article cites a case of possible central anticholinergic syndrome following transdermal scopolamine in an ambulatory surgery patient reported in the "Canadian Journal of Anesthesia."

  • Scopolamine hydrobromide.  // Reactions Weekly;7/21/2012, Issue 1411, p40 

    The article presents a case study of a teenage girl who developed unilateral mydriasis while receiving scopolamine hydrobromide transdermal patch.

  • Scopolamine withdrawal.  // Reactions Weekly;Sep2014, Vol. 1518 Issue 1, p145 

    An abstract of the article "Scopolamine patch withdrawal syndrome" by S. H. Lau and colleagues is presented.

  • SCOPOLAMINE (Hyoscine).  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p738 

    The article presents information on scopolamine or hyoscine, an antispasmodic and anticholinergic agent, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • SCOPOLAMINE (Hyoscine). GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2009, p746 

    The article presents information on scopolamime, an antispasmodic and anticholinergic drug, including dosage, usage, adverse reactions, side effects, precautions, and possible interaction with other drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics